ACN-1052 for Glaucoma
Inhibition of a G-protein coupled receptor in the eye is a novel and effective mechanism for treating glaucoma. ACN-1052 is the lead molecule in a class of selective receptor antagonists that substantially lowers intraocular pressure when topically administered to the eye of normal mice and rabbits. This compound has been shown to readily cross the cornea, reduce the production of aqueous humor, and provide long lasting reduction of intraocular pressure. In a monkey model of glaucoma, a single dose of ACN-1052 administered to the eye significantly reduced intraocular pressure. ACN-1052 compares favorably in animals to the three major commercial glaucoma therapies.
Glaucoma currently affects more than 67 million people worldwide and is the second leading cause of irreversible blindness in the world. By 2010, the incidence of new glaucoma cases is projected to be 3.6 million in the U.S. In 2008, the Global market for glaucoma therapies was estimated at $5.0 Billion.
|
